Novel application of lentiviral vectors towards treatment of graft-versus-host disease

Expert Opinion on Biological Therapy

Volumn 9, Issue 6, 2009, Pages 749-761

  Scaife, Matthew D ^b   Neschadim, Anton ^b   Fowler, D H ^c   Medin, J A ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allogeneic bone marrow transplantation (allo BMT); Cell fate control gene therapy (CFCGT); Donor lymphocyte infusion (DLI); Gene therapy; Graft versus host disease (GvHD); Hematopoietic cell transplantation (HCT); Lentivirus; Suicide gene therapy

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ALEMTUZUMAB; CASPASE 9; CLADRIBINE; CLOFARABINE; CYCLOSPORIN A; CYTARABINE; CYTOSINE DEAMINASE; DEOXYCYTIDINE KINASE; FK 506 BINDING PROTEIN; FLUCYTOSINE; FLUDARABINE; GANCICLOVIR; GEMCITABINE; LENTIVIRUS VECTOR; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NERVE GROWTH FACTOR; OUABAIN; PURINE NUCLEOSIDE PHOSPHORYLASE; RAPAMYCIN; TACROLIMUS; THYMIDINE KINASE; UNINDEXED DRUG; ZIDOVUDINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL FATE; CELL FATE CONTROL GENE THERAPY; CELL SURVIVAL; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE TARGETING; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS 1; HLA MATCHING; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MYELOABLATIVE CONDITIONING; NONHUMAN; REDUCED INTENSITY CONDITIONING; REVIEW; SUICIDE GENE THERAPY; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

CELL LINEAGE; GENE THERAPY; GENETIC VECTORS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENTIVIRUS; TRANSPLANTATION, HOMOLOGOUS;

LENTIVIRUS;

EID: 67649120068     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903002021     Document Type: Review

References (107)

1. Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008;299:925-936
2. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant 2008;42(Suppl 1):S49-S52
3. Pasquini MC. Impact of graft-versus-host disease on survival. Best Pract Res Clin Haematol 2008;21:193-204 (Pubitemid 351714759)
4. Willmon CL, Krabbenhoft E, Black ME. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Ther 2006;13:1309-1312 (Pubitemid 44264085)
5. Kokoris MS, Black ME. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci 2002;11:2267-2272 (Pubitemid 34919630)
6. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006;107:2294-2302 (Pubitemid 43345547)
7. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223 (Pubitemid 26057556)
8. Thomas ED, Lochte HL Jr, Cannon JH, et al. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 1959;38:1709-1716
9. Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol 2008;21:101-117
10. Billingham RE. The biology of graft-versus host reactions. Harvey Lect 1966;62:21-78
11. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol 1988;69:239-245 (Pubitemid 18161106)
12. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562 (Pubitemid 20069191)
13. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050
14. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-1268
15. Porter DL, Connors JM, Van Deerlin VM, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999;17:1234-1243 (Pubitemid 29162949)
16. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007;109:4698-4707 (Pubitemid 46827761)
17. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002;20:405-412 (Pubitemid 34072522)
18. Aschan J. Allogeneic haematopoietic stem cell transplantation: current status and future outlook. Br Med Bull 2006;77-78:23-36 (Pubitemid 46092271)
19. Gahrton G. Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. Best Pract Res Clin Haematol 2007;20:219-229 (Pubitemid 46591153)
20. Petersdorf EW. Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol 2007;20:155-170 (Pubitemid 46585965)
21. Dickinson AM, Harrold JL, Cullup H. Haematopoietic stem cell transplantation: can our genes predict clinical outcome? Expert Rev Mol Med 2007;9:1-19
22. Dickinson AM. Non-HLA genetics and predicting outcome in HSCT. Int J Immunogenet 2008;35:375-380
23. Nordlander A, Uzunel M, Mattsson J, Remberger M. The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. Br J Haematol 2002;119:1133-1136 (Pubitemid 35463843)
24. Kim DH, Lee NY, Sohn SK, et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation 2005;79:1615-1622 (Pubitemid 40847595)
25. Rocha V, Porcher R, Fernandes JF, et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009;23:545-556
26. Buzzeo MP, Yang J, Casella G, Reddy V. A preliminary gene expression profile of acute graft-versus-host disease. Cell Transplant 2008;17:489-494
27. Kircher B, Niederwieser D, Gachter A, et al. T-cell precursor frequencies and long-term outcome following unrelated hematopoietic stem cell transplantation. Int J Lab Hematol 2008;30:499-507
28. Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 2006;57:225-244 (Pubitemid 43238327)
29. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007;137:87-98 (Pubitemid 46474711)
30. Barret AJ, Le Blanc K. Prophylaxis of acute GVHD: manipulate the graft of the environment? Best Pract Res Clin Haematol 2008;21:165-176
31. Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma 2005;46:1251-1260 (Pubitemid 41269290)
32. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007;20:281-294 (Pubitemid 46585971)
33. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990;75:1024-1030 (Pubitemid 20067206)
34. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991;77:1821-1828
35. Sorror ML, Leisenring W, Deeg HJ, et al. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant 2005;11:814-815 (Pubitemid 41403763)
36. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989;72:567-572 (Pubitemid 19220499)
37. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993;81:1094-1101
38. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004;104:649-654 (Pubitemid 38970556)
39. Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:1224-1226 (Pubitemid 39038048)
40. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273-277
41. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007;110:2764-2767 (Pubitemid 47523204)
42. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21:1733-1738 (Pubitemid 47086763)
43. Zhi-Gang Z, Wei-Ming L, Zhi-Chao C, et al. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases. Leuk Lymphoma 2008;49:2187-2195
44. Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007;109:374-382 (Pubitemid 46053080)
45. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004;10:987-992 (Pubitemid 39273741)
46. Mariotti J, Foley J, Jung U, et al. Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Immunol 2008;180:89-105
47. Foley JE, Jung U, Miera A, et al. Ex vivo rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism. J Immunol 2005;175:5732-5743 (Pubitemid 41508056)
48. Foley JE, Mariotti J, Ryan K, et al. Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol Blood Marrow Transplant 2008;14:959-972
49. Michalek J, Collins RH, Durrani HP, et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4 + T cells by virtue of their receptor β loci sequences. Proc Natl Acad Sci USA 2003;100:1180-1184 (Pubitemid 36183976)
50. Michalek J, Collins RH, Hill BJ, et al. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet 2003;361:1183-1185 (Pubitemid 36398389)
51. Tey SK, Dotti G, Rooney CM, et al. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007;13:913-924 (Pubitemid 47055386)
52. Montagna D, Daudt L, Locatelli F, et al. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction. Cancer Res 2006;66:7310-7316 (Pubitemid 44197713)
53. Qasim W, Mackey T, Sinclair J, et al. Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol Ther 2007;15:355-360 (Pubitemid 46111886)
54. Plautz G, Nabel EG, Nabel GJ. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol 1991;3:709-715
55. Deschamps M, Mercier-Lethondal P, Certoux JM, et al. Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. Blood 2007;110:3842-3852 (Pubitemid 350248439)
56. Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003;101:1290-1298 (Pubitemid 36182498)
57. Mercier-Letondal P, Deschamps M, Sauce D, et al. Early immune response against retrovirally-transduced Herpes Simplex Virus-thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft : an altered immune response? Hum Gene Ther 2008;19:937-950
58. Blumenthal M, Skelton D, Pepper KA, et al. Effective suicide gene therapy for leukemia in a model of insertional oncogenesis in mice. Mol Ther 2007;15:183-192 (Pubitemid 46043664)
59. Pellicer A, Wagner EF, el-Kareh A, et al. Introduction of a viral thymidine kinase gene and the human β-globin gene into developmentally multipotential mouse teratocarcinoma cells. Proc Natl Acad Sci USA 1980;77:2098-2102
60. Bordignon C, Bonini C, Verzeletti S, et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 1995;6:813-819
61. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001;97:63-72 (Pubitemid 32061243)
62. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724 (Pubitemid 27421983)
63. Moolten FL, Wells JM, Heyman RA, Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990;1:125-134 (Pubitemid 120034723)
64. Qasim W, Thrasher AJ, Buddle J, et al. T cell transduction and suicide with an enhanced mutant thymidine kinase. Gene Ther 2002;9:824-827 (Pubitemid 34679311)
65. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001;61:3022-3026 (Pubitemid 32691949)
66. Chalmers D, Ferrand C, Apperley JF, et al. Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 2001;4:146-148 (Pubitemid 32776506)
67. Garin MI, Garrett E, Tiberghien P, et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001;97:122-129 (Pubitemid 32061251)
68. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-178 (Pubitemid 23034801)
69. Sato T, Neschadim A, Konrad M, et al. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 2007;15:962-970 (Pubitemid 46621655)
70. Ostermann N, Lavie A, Padiyar S, et al. Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP. J Mol Biol 2000;304:43-53
71. Lavie A, Schlichting I, Vetter IR, et al. The bottleneck in AZT activation. Nat Med 1997;3:922-924 (Pubitemid 27353456)
72. Sabini E, Ort S, Monnerjahn C, et al. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 2003;10:513-519 (Pubitemid 36792901)
73. Neschadim A, Lavie A, Sao T, et al. Novel lentiviral cell fate control gene therapy based on engineered variants of the human deoxycytidine kinase [abstract]. Mol Ther 2008;16:S212
74. McSorley T, Ort S, Hazra S, et al. Mimicking phosphorylation of Ser-74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analogues. FEBS Lett 2008;582:720-724
75. Mavilio F, Ferrari G, Rossini S, et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994;83:1988-1997 (Pubitemid 24107926)
76. Klimatcheva E, Rosenblatt JD, Planelles V. Lentiviral vectors and gene therapy. Front Biosci 1999;4:D481-96
77. Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 2003;102:497-505 (Pubitemid 36841966)
78. Cattoglio C, Facchini G, Sartori D, et al. Hot spots of retroviral integration in human CD34 + hematopoietic cells. Blood 2007;110:1770-1778 (Pubitemid 47443887)
79. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521-529 (Pubitemid 35232295)
80. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 2006;13:1031-1049 (Pubitemid 43779188)
81. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003;3:477-488 (Pubitemid 37328836)
82. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-419 (Pubitemid 37296260)
83. Zhou X, Cui Y, Huang X, et al. L entivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther 2003;14:1089-1105 (Pubitemid 36851400)
84. Verhoeyen E, Dardalhon V, Ducrey-Rundquist O, et al. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 2003;101:2167-2174 (Pubitemid 36302054)
85. Costello E, Munoz M, Buetti E, et al. Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther 2000;7:596-604 (Pubitemid 30175563)
86. Chinnasamy D, Chinnasamy N, Enriquez MJ, et al. Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 2000;96:1309-1316 (Pubitemid 30662030)
87. Dardalhon V, Jaleco S, Rebouissou C, et al. Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector. Blood 2000;96:885-893 (Pubitemid 30616852)
88. Frecha C, Costa C, Negre D, et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 2008;112:4843-4852
89. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-696 (Pubitemid 43882120)
90. De Palma M, Montini E, Santoni de Sio FR, et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 2005;105:2307-2315 (Pubitemid 40387024)
91. Mitchell RS, Beitzel BF, Schroder AR, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004;2:E234, published online 17 August, 2004, doi:10.1371/journal.pbio.0020234 (Pubitemid 39245268)
92. Neschadim A, McCart JA, Keating A, Medin JA. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13:1407-1416 (Pubitemid 350091394)
93. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103:17372-17377 (Pubitemid 44788976)
94. Di Ianni M, Di Florio S, Venditti G, et al. T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection. Cancer Gene Ther 2000;7:920-926 (Pubitemid 30437294)
95. Sauce D, Bodinier M, Garin M, et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002;99:1165-1173 (Pubitemid 37258302)
96. Zielske SP, Gerson SL. Lentiviral transduction of P140K MGMT into human CD34 + hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol Ther 2002;5:381-387 (Pubitemid 34308662)
97. Treschow A, Unger C, Aints A, et al. OuaSelect, a novel ouabain-resistant human marker gene that allows efficient cell selection within 48 h. Gene Ther 2007;14:1564-1572 (Pubitemid 350056228)
98. Medin JA, Migita M, Pawliuk R, et al. A bicistronic therapeutic retroviral vector enables sorting of transduced CD34 + cells and corrects the enzyme deficiency in cells from Gaucher patients. Blood 1996;87:1754-1762 (Pubitemid 26068891)
99. van Meerten T, Claessen MJ, Hagenbeek A, Ebeling SB. The CD20/αCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther 2006;13:789-797
100. Ramsubir S, Nonaka T, Girbes CB, et al. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol Genet Metab 2008;95:133-141
101. Migita M, Medin JA, Pawliuk R, et al. Selection of transduced CD34 + progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc Natl Acad Sci USA 1995;92:12075-12079 (Pubitemid 26014014)
102. Rettig MP, Ritchey JK, Meyerrose TE, et al. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Mol Ther 2003;8:29-41 (Pubitemid 36939294)
103. Junker K, Koehl U, Zimmerman S, et al. Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes. Gene Ther 2003;10:1189-1197 (Pubitemid 36896594)
104. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994;91:8302-8306 (Pubitemid 24985018)
105. Gadi VK, Alexander SD, Kudlow JE, et al. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 2000;7:1738-1743
106. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247-4254 (Pubitemid 40720769)
107. Thomis DC, Marktel S, Bonini C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001;97:1249-1257 (Pubitemid 32183746)